3Settimana·

Krystal Biotech

1
14 Commenti

immagine del profilo
🍎🍐
3
immagine del profilo
immagine del profilo
@Memo0606 Apples and pears. You can't compare them
2
immagine del profilo
@AlterMann yes i actually understood that... one is a boring dividend stock the other is growth
i'll have to think about whether i want wher share price gains or dividends 😅
immagine del profilo
@Memo0606 and how is anyone supposed to help you - if that's even possible... 😂😂🤷‍♂️
1
immagine del profilo
@AlterMann maybe someone has an opinion on krys
immagine del profilo
The pharmaceutical sector is likely to remain volatile due to Trump's drug regulations
1
immagine del profilo
However, a P/E ratio of 21 with triple-digit earnings growth is already brilliant.
This lowers the P/E ratio to 15, which should be an incentive to buy.
1
immagine del profilo
@Tenbagger2024 i am sure the value will rise
but for that i would have to create cash by selling j&j... or sell novo
maybe i'll also sell part of him tomorrow
immagine del profilo
@Memo0606
I also see potential there and had bought again
1
immagine del profilo
@Tenbagger2024 if you look at my portfolio my friend
where would you make purchases?
immagine del profilo
@Memo0606
Difficult to say. I advised against Merck when I bought it and you can't really see a bottom here yet.
I think there should be a turnaround with UFP Technologie.
Fortescue still needs patience, and you would of course miss out on dividends if you sold.
1
immagine del profilo
@Tenbagger2024 yes, i am disappointed with merck
if necessary, I'll make a change from merck and buy $KRYS
immagine del profilo
@Memo0606
Merck is now valued very favorably in terms of its P/E ratio. And it continues to grow.
That's why a bottom should actually form soon.
Because the share is now really cheap.
So you could be annoyed if you sell at the current valuation
1
Partecipa alla conversazione